Incannex Healthcare(NASDAQ) IXHL

Incannex develops medicines using cannabinoids and psychedelics for chronic health conditions. Its products aim to help people with sleep apnea, brain injuries, and anxiety. The company focuses on patients who lack effective treatment options.

What’s in the Medicine Cabinet? (Products and Services)

• Obstructive Sleep Apnea Therapy (IHL-42X): Experimental treatment for people with sleep-related breathing problems; no revenue contribution disclosed.
• Brain Injury Solution (IHL-216A): Drug in development for traumatic brain injury and sports concussion; no revenue contribution disclosed.
• Inflammatory Disease Combo (IHL-675A): Combines hydroxychloroquine and cannabidiol for lung and autoimmune diseases; no revenue contribution disclosed.
• Anxiety Disorder Therapy (PSX-001): Psilocybin-based treatment for generalized anxiety disorder; no revenue contribution disclosed.
• Pharmaceutical-Grade Cannabinoids: Sold under the Incannex brand, mainly in Australia; minimal revenue contribution.
• Patient Services (Clarion Clinics): Provides clinical services to patients; generated $86,000 in revenue for nine months ended March 31, 2025.

Growth Spurts and Strategic Moves

• Partnered with The Alfred Hospital and Novotech for sleep apnea drug trials (2023–2025).
• Collaborated with Monash Trauma Group at Monash University for brain injury research (2023–2025).
• Launched Clarion Clinics to deliver patient services (2024).
• Raised $12.5 million in private placement (March 2025).
• Paused Australian trial for IHL-675A to focus on U.S. regulatory pathway (2025).

Why Incannex Is a Bit Different

Incannex targets diseases with few approved treatments using cannabinoid and psychedelic drugs. It leverages Australian research incentives and global partnerships to advance clinical programs. The company operates with a small team and relies on external funding and government support.

Five Things You Need to Know

• Revenue was $66,616 in Q4 2025, up 270.8% from Q4 2024.
• Net loss was $13 million in Q4 2025, improving 14.1% from Q4 2024.
• Cash used in operations was $1 million in Q4 2025, improving 70.1% year-over-year.
• Market cap was $92.68 million as of February 13, 2026.
• R&D tax incentive income was $0.42 million in Q1 2025, down 68% year-over-year.

Bottom Line

Incannex is a clinical-stage company focused on cannabinoid and psychedelic medicines for unmet medical needs. It remains pre-commercial, relying on research incentives and external funding to advance its drug pipeline.